We are live on ! Find out more
LOGC

LogicBio Therapeutics, Inc. Common Stock
LOGC

Delisted

LOGC was delisted on the 15th of November, 2022.

Back to rankings

57 hedge funds and large institutions have $37M invested in LogicBio Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

0% more funds holding

Funds holding: 57 → 57 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

49% less capital invested

Capital invested by funds: $73.2M → $37M (-$36.2M)

84% less call options, than puts

Call options by funds: $5K | Put options by funds: $32K

Holders
57
Holders Change
–
Holders Change %
0%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
12
Reduced
10
Closed
11
Calls
$5K
Puts
$32K
Net Calls
-$27K
Net Calls Change
+$16K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$1.58M
2
Millennium Management
Millennium Management
New York
+$293K
3
SC
Samlyn Capital
New York
+$126K
4
William Blair & Company
William Blair & Company
Illinois
+$74.3K
5
Citadel Advisors
Citadel Advisors
Florida
+$62.9K

Top Sellers

Rank Fund Capital Flow
1
LPC
Lion Point Capital
New York
-$2.29M
2
E
Ergoteles
New York
-$301K
3
Renaissance Technologies
Renaissance Technologies
New York
-$216K
4
EP
Eversept Partners
New York
-$199K
5
HF
HRT Financial
New York
-$192K
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
26
Virtu Financial
New York
$40K +$58.6K +17,330 New
SMH
27
Sanders Morris Harris
Texas
$35K -$67.7K -20,000 -57%
HSBC Holdings
28
HSBC Holdings
United Kingdom
$35K – – –
Barclays
29
Barclays
United Kingdom
$34K -$8.66K -2,561 -15%
Morgan Stanley
30
Morgan Stanley
New York
$32K +$10.9K +3,215 +30%
IBOK
31
Independence Bank of Kentucky
Kentucky
$30K +$43.6K +12,875 New
Commonwealth Equity Services
32
Commonwealth Equity Services
Massachusetts
$29K +$244 +72 +0.6%
Charles Schwab
33
Charles Schwab
California
$27K – – –
Bank of New York Mellon
34
Bank of New York Mellon
New York
$25K – – –
Walleye Capital
35
Walleye Capital
New York
$25K +$37K +10,924 New
Connor, Clark & Lunn Investment Management (CC&L)
36
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$25K +$37.1K +10,974 New
Simplex Trading
37
Simplex Trading
Illinois
$22K +$30K +8,865 +1,080%
UBS Group
38
UBS Group
Switzerland
$17K -$186K -54,932 -88%
EWM
39
Endurance Wealth Management
Rhode Island
$12K – – –
Bank of America
40
Bank of America
North Carolina
$11K -$6.8K -2,009 -30%
Osaic Holdings
41
Osaic Holdings
Arizona
$11K +$281 +83 +2%
TRCT
42
Tower Research Capital (TRC)
New York
$7K +$6.32K +1,869 +163%
US Bancorp
43
US Bancorp
Minnesota
$5K – – –
LWANC
44
Laurel Wealth Advisors (North Carolina)
North Carolina
$4K – – –
Wells Fargo
45
Wells Fargo
California
$3K – – –
Group One Trading
46
Group One Trading
Illinois
$3K +$3.72K +1,100 New
FDCDDQ
47
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.08K – – –
APC
48
Aspire Private Capital
North Carolina
$2K – – –
BNP Paribas Financial Markets
49
BNP Paribas Financial Markets
France
$1.01K -$169 -50 -10%
CAPTRUST Financial Advisors
50
CAPTRUST Financial Advisors
North Carolina
$1K – – –
1
2
3

LOGC Hedge Fund Activity: Q4 2021 in Review

57 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q4 2021, worth a combined $37M — down 49% from $73.2M a quarter earlier.

Fund positioning in LOGC was balanced in Q4 2021: 11 funds opened new positions, 11 closed out, 12 added to existing stakes and 10 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $1.58M. The largest seller was Lion Point Capital, exiting entirely with an estimated $2.29M sold.

  • 57 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q4 2021, unchanged from Q3 2021.
  • Funds reported $37M of LogicBio Therapeutics, Inc. Common Stock stock for Q4 2021, down 49% quarter-over-quarter.
  • 11 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q4 2021 and 11 closed out, a net change of 0 holders.
  • The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q4 2021 was Goldman Sachs, an estimated $1.58M added.
  • The largest LogicBio Therapeutics, Inc. Common Stock seller in Q4 2021 was Lion Point Capital, an estimated $2.29M sold.

Based on aggregated 13F filings for Q4 2021.